Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q1 2025 Earnings Presentation

37 slides from Neurocrine Biosciences's earnings presentation, May 5, 2025

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q1 2025 Earnings Presentation May 5, 2025

  2. Slide 2: Safe Harbor and Forward-Looking Statements

    Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products an

  3. Slide 3: Where Are We Today?

    Where Are We Today? Discovered and Developed Four Novel FDA-Approved Programs Neurocrine Discovered / Developed In the U.S. Deep Expertise in Neuroscience Drug Development Fully-Integrated Organization with R&D and Commercial Capabilities * Growing Blockbuster Commercial Product in INGREZZA with Str

  4. Slide 4: Well-Positioned for Sustained & Long-Term Growth

    Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic Area 2025 INGREZZA Annual Net • Neuropsychiatry Diversification Sales Guidance Reaffirmed TARDIVE DYSKINESIA AND HUNTINGTON

  5. Slide 5: Our Pipeline Today – 12 Programs

    Our Pipeline Today – 12 Programs Modality Key Small Molecule PROGRAM (TARGET) MODALITY THERAPEUTIC AREA INDICATION PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychiatry Adjunctive Treatment of Schizophrenia valbenazine (VMAT2 Inhibitor) Neurology Dyskinetic Cerebral Palsy Inadequate

  6. Slide 6: Q1 2025 Highlights and 2025 Key Milestones / Activities

    Q1 2025 Highlights and 2025 Key Milestones / Activities Q1 2025 Highlights 2025 Key Milestones / Activities ▪ CRENESSITYTM (crinecerfont) Net Product Sales of $14.5M Including ▪ Reaffirmed INGREZZA Net Sales Guidance of $2.5 - $2.6B 413 Total Patient Enrollment Forms ▪ Successfully Launch CRENESSITY

  7. Slide 7: Q1 2025 Financial Summary

    Q1 2025 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q1 2025 Q1 2024 Highlights / Comments Revenue $573 $515 INGREZZA Sales of $545M Represents YoY Growth of 8% Driven by Underlying Patient Demand Including Record - INGREZZA Net Product Sales $545 $506 New Patient Starts and

  8. Slide 8: 2025 INGREZZA Net Sales and Expense Guidance Reaffirmed

    2025 INGREZZA Net Sales and Expense Guidance Reaffirmed 2025 Guidance Range Item ($ Millions) 2024 Actuals Reaffirmed INGREZZA Net Product Sales1 $2,314 $2,500 - $2,600 GAAP R&D Expense2 $731 $960 - $1,010 Non-GAAP R&D Expense2, 3 $662 $890 - $940 GAAP SG&A Expense4 $1,007 $1,110 - $1,130 Non-GAAP S

  9. Slide 9: Our Medicines, Our Patients

    Our Medicines, Our Patients 9

  10. Slide 10: INGREZZA (valbenazine) capsules

    NEUROGRINE INGREZZA (valbenazine) capsules

  11. Slide 11: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  12. Slide 12: Nascent Tardive Dyskinesia Market Presents Significant Opportunity

    Nascent Tardive Dyskinesia Market Presents Significant Opportunity ESTIMATED TO AFFECT ~800,000 Nearly 9 of 10 TD PATIENTS ARE NOT CURRENTLY people in the U.S. TREATED WITH A VMAT2 INHIBITOR LIKE INGREZZA Source: U.S.Claims Data and 31 Global Scientific Publications; U.S. Tardive Dyskinesia Prevalen

  13. Slide 13: INGREZZA Approved by the FDA for Chorea Associated with Huntington's Disease

    INGREZZA® Approved by the FDA for the Treatment of Chorea Associated with Huntington’s Disease INGREZZA Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In randomized, double-blind

  14. Slide 14: CRENESSITY

    yd mn Crenessity™ PeNeoolty NEUROCRINE’ BIOSCIENCES

  15. Slide 15: CRENESSITY Offers Potential to Change Standard of Care

    CRENESSITY Offers Potential to Change Standard of Care First New Treatment Available for Classic CAH in 70 Years ABOUT CRENESSITY ABOUT CONGENITAL ADRENAL HYPERPLASIA • Q1 Net Sales of $14.5M with 413 New Patient • Rare and Life-long Genetic Condition that Affects Enrollment Forms ~20,000 Pediatric

  16. Slide 16: Neuropsychiatry Pipeline

    Neuropsychiatry Pipeline 16

  17. Slide 17: Osavampator: Initiated All Registration Enabling Phase 3 Studies for MDD

    Osavampator* (AMPA Potentiator): Initiated All Registration Enabling Phase 3 Studies for the Treatment of MDD Inadequate Response to Treatment osavampator in Major Depressive Disorder (MDD) ~1/3 of the 16 Million+ People in the U.S. Potent First-in-Class AMPA potentiator Who Live with MDD Do Not Res

  18. Slide 18: Osavampator SAVITRI Phase 2 Study Summary Results

    TM Osavampator* (AMPA Potentiator) SAVITRI Phase 2 Study Summary Results EFFICACY SAFETY AND TOLERABILITY • Met Primary and Key Secondary Endpoints • Osavampator was Generally Well-tolerated • Once-Daily, Oral Administration of osavampator • Most Common Adverse Events: Headache Produced a Statistica

  19. Slide 19: Muscarinic Platform Includes Multiple Clinical Programs

    Muscarinic Platform Includes Multiple Clinical Programs From M1 to M4 Selective Orthosteric Agonists M1 M1 / M4 M4 “Cognition” DUAL “Psychosis” ▪ Phase 1 PREFERRING ▪ Advancing into Phase 2 in PREFERRING Schizophrenia in 2H 2025 ▪ Phase 1 ▪ Phase 1 NBI- NBI- ’570 NBI- SELECTIVE SELECTIVE ’567 ’569 ▪

  20. Slide 20: Summary of NBI-'568 Positive Phase 2 Topline Results

    Summary of NBI-’568* Positive Phase 2 Topline Results Once-Daily 20mg Dose: Efficacy, Safety, and Tolerability Results Support Advancement to Phase 3 in 1H 2025 Additional Phase 2 Study Details to be Shared Later in 2025 20mg Once-daily Demonstrated Efficacy, Safety and Tolerability Profile Statisti

  21. Slide 21: Once-Daily 20mg Dose Demonstrated Efficacy at Week 3, 4, 5, and 6

    Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6 0 20mg QD Efficacy Data PANSS Total Score Change from Baseline LS Mean1 ± SEM -5.7 Week 4 – Week 6 -5 -8.2 -7.7 Week 4 5 6** -9.6 PANSS Total Score -8.4 -10.2 -10 -10.8 -11.5 LS Mean

  22. Slide 22: Once-Daily 20mg Dose Improvement in Additional Endpoints

    Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints \ CGI-S Marder Factor — Positive Marder Factor — Negative Placebo 20mg QD Placebo 20mg QD Placebo 20mg QD Week 6 N=68 N=35 N=68 N=35 N=68 N=35 LS Mean Change from Baseline* -0.5 -1.2 -2.8 -5.8 -1.2 -3.1 L

  23. Slide 23: NBI-'568 Was Generally Safe and Well Tolerated at All Doses Studied

    NBI-’568 Was Generally Safe and Well Tolerated at All Doses Studied Treatment-Emergent Adverse Events Occurring in ≥ 5% of NBI-'568 All Treated Group Placebo 20mg QD 40mg QD 60mg QD 30mg BID All Treated \ N=70 N=40 N=39 N=34 N=27 N=140 Somnolence 2 (2.9) 5 (12.5) 2 (5.1) 7 (20.6) 1 (3.7) 15 (10.7) D

  24. Slide 24: NBI-'568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist

    NBI-’568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development Type of Requires Endogenous Large Opportunity For NBI-'568, Subtype Muscarinic Ligand A Novel And Differentiated Asset Selectivity Activation (Acetylcholine) With No Reliance on Innate Acetylcholine Le

  25. Slide 25: NBI-'568 Effect Size Comparable to Known Muscarinic Programs

    NBI-’568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics Muscarinic Programs Leading Approved Treatments 0.75 0.61 0.61 0.6 0.56 Effect Size 0.55 0.42 0.41 0.36 0.34 0.3 0.26 125mg / 30mg BID 125mg / 30mg BID 20mg NBI-568 QD 125mg / 30mg BID Zyprexa Risperdal Seroquel

  26. Slide 26: Valbenazine: Phase 3 ATS Study to Inform Next-Generation VMAT2 Inhibitors

    Valbenazine*: Phase 3 ATS Study to Inform Next-Generation VMAT2 Inhibitors Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is One of the WW Leading Causes of Disability, Affecting Up to 3.5M People in the U.S. Schizophrenia is a Serious, Chronic Mental Illness that Causes Abnormal Thoughts

  27. Slide 27: Neurology Pipeline

    Neurology. : Reo [ies ae j FD se. a= Oo Brosciences You Des

  28. Slide 28: Neurology Programs in Clinical Development

    Neurology Programs in Clinical Development Valbenazine* Valbenazine in ATS NBI-’890* RESEARCH and NBI-’675* & DEVELOPMENT NBI-’355*POSITION STRONG FINANCIAL • VMAT2 Inhibitor • Next Generation VMAT2 Inhibitors • Selective Nav1.2 / Nav1.6 Inhibitor • Ongoing Phase 3 Study in Dyskinetic ✓ NBI-’890 and

  29. Slide 29: R&D Will Deliver A New Medicine Every Two Years

    R&D Will Deliver A New Medicine Every Two Years Multimodality Mid-stage pipeline focused on clinically Commitment to R&D innovation engine or genetically validated targets R&D Sustainability Research 4+ Phase 1 Starts Target Level of Productivity Each Year 2+ Phase 2 Starts (On Average) 3+ Phase 3 P

  30. Slide 30: Our Pipeline Tomorrow – 18 Programs

    Modality Key Small Molecule Peptide Antibody Gene Therapy Our Pipeline Tomorrow – 18 Programs Study Status Key End of 2025 Current Study Study Initiating P R O G R AM ( T A R G E T ) M O D AL I T Y THERAPEUTIC AREA I N D I C A T I ON PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychia

  31. Slide 31: Well-Positioned for Sustained & Long-Term Growth

    Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic Area 2025 INGREZZA Annual Net • Neuropsychiatry Diversification Sales Guidance Reaffirmed TARDIVE DYSKINESIA AND HUNTINGTON

  32. Slide 32: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations

  33. Slide 33: Condensed Consolidated Statements of Income

    NNEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three Months Ended March 31, (in millions, except per share data) 2025 2024 Revenues: Net product sales $ 563.7 $ 509.0 Collaboration revenue 89 63 Total revenues 572.6 $15.3 Operating expenses: Cost of revenues 92

  34. Slide 34: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) March 31, (in millions) 2025 Cash, cash equivalents, and marketable securities $ 943.5 Other current assets 694.4 Total current assets 1,637.9 Deferred tax assets 499.4 Marketable securities 8153 Right-of-use assets 502.2

  35. Slide 35: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE’ BIOSCIENCES NNEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) (in millions, except per share data) GAAP net income ! Adjustments: Stock-based compensation expense - R&D 23.0 17.0 Stock-based compensation expense - SG&A. 29.8 275 Charges associ

  36. Slide 36: Reconciliation of GAAP to Non-GAAP Expenses

    ‘NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) (im milions) GAAP cost of: Adjustments: ‘Non-cash amortization related to acquired intangible assets Non-GAAP cost of revenues (in milions) GAAPR&D Adjustments: Stock-based compensation expense Non-GAAP R&D (in mil

  37. Slide 37: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q1 2025 Earnings Presentation May 5, 2025

Neurocrine Biosciences — Q1 2025 Earnings Presentation on 6ix